Q
QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

30,605 signal articles · 128 in last 24h · 155,437 total before filter · latest 42m ago
128last 24h
855last 7d
146● bullish (7d)
90● bearish (7d)
214publishers
AllMacro191Earnings105M&A126Regulatory20Product22Analyst19
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearishshow all (incl. clickbait)
POET Technologies (POET) Soars 27% Ahead of This Week’s Earnings
Insider Monkey137d agobullish
POET Technologies (POET) Soars 27% Ahead of This Week’s Earnings

POET Technologies Inc. (NASDAQ:POET) is one of the 10 Stocks With Easy Double-Digit Returns. POET Technologies rallied for a second day on Monday, climbing 27.09 percent to close at $13.90 apiece, as investors resumed buying positions ahead of the results of its earnings performance this week. Based on its historical reporting dates, POET Technologies Inc. […]

Everpure Stock Rallies As Data Storage Player Nears Earnings Test
Investor's Business Daily137d agobullish
Everpure Stock Rallies As Data Storage Player Nears Earnings Test

Everpure stock jumped Monday ahead of the data storage company's earnings. The company, which recently changed its name from Pure Storage, is  rallying ahead of an earnings report due later this month. Everpure stock is up more than 13% at 88.80 in recent trading on the stock market today Monday.

A Look At CVS Health (CVS) Valuation After Earnings Beat And Raised 2026 Guidance
Simply Wall St.137d agobullish
A Look At CVS Health (CVS) Valuation After Earnings Beat And Raised 2026 Guidance

CVS Health (CVS) is back in focus after first quarter 2026 results and raised full year guidance, with management highlighting broad based strength across Aetna, Health Services, and Pharmacy & Consumer Wellness. See our latest analysis for CVS Health. After the earnings beat and guidance raise, the share price has climbed to US$90.55, with a 1 month share price return of 14.14% and a 1 year total shareholder return of 44.83%. This suggests momentum has picked up recently compared with longer...